MSF pushes down price of generic hepatitis C drugs to new low levelBMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j5054 (Published 01 November 2017) Cite this as: BMJ 2017;359:j5054
- Jacqui Wise
The medical humanitarian charity Médecins sans Frontières (MSF) has secured deals on generic formulations of the hepatitis C treatments sofosbuvir and daclatasvir for as low as US $1.40 (£1.05; €1.20) a day or $120 for a 12 week course.1 This is a dramatic reduction on the original price tag of $147 000 for a 12 week course of the branded versions.
MSF is calling on governments worldwide to work harder to bring down prices of hepatitis C drugs to a similar low level to expand access to treatment.
The combination of sofosbuvir and daclatasvir has been shown to be highly effective in treating hepatitis C virus infection, with cure rates of up to 95% and fewer side effects than with previous treatments. But access to the direct acting antivirals has been limited in …